Programmed death‐ligand 1 (PD‐L1) expression levels were assessed retrospectively as a potential biomarker for nivolumab therapy in CheckMate 040, using a cut‐off of membrane expression of PD‐L1 on ≥1% of tumour cells. This evidence concerns the gene CD274 and neoplasm.